Why The Focus Is On Cara Therapeutics Inc (NASDAQ:CARA)?

Why The Focus Is On Cara Therapeutics Inc (NASDAQ:CARA)?

Enteris BioPharma, Inc., a biotech firm advancing unique drug offerings made around its proprietary delivery technologies, applauded Cara Therapeutics Inc (NASDAQ:CARA) on the successful commencement of its Phase I clinical study of its oral formulation of CR845 in people with stage III-V chronic kidney disease, who are not on dialysis.

The details

An oral tablet formulation of CR845, was engineered utilizing Enteris’ proprietary oral delivery know-how, Peptelligence™. This formulation of CR845 was advanced as per a Manufacturing and Clinical Supply Deal between Enteris and Cara Therapeutics whereby Enteris used its Peptelligence™ know-how to enable the active ingredient, which was preliminary formulated for I.V. administration, to be given orally.

As per the “Feasibility-to-Licensing” plan, Enteris will continue to develop the oral tablet formulation of ‘CR845’ for potential and current future trials through Phase II that Cara Therapeutics chooses to pursue. The company has the alternative to negotiate a license to the Peptelligence™ know-how for Oral CR845 from Enteris BioPharma at any time.

Joel Tune, the Executive Chairman and CEO of Enteris BioPharma, expressed that they congratulate Cara Therapeutics on the commencement of its Phase 1 clinical study of Oral CR845 in non-hemodialysis CKD and the prospect for company to use data from this trial to inform dose selection and design of an intended placebo-controlled Phase II study in people with CKD-aP.

Extending Oral CR845 into the pruritus treatment, in addition to chronic pain, further showcases the prospect of their oral drug delivery platform, Peptelligence™. It has been shown to be well tolerated and safe oral delivery system and has shown clinically meaningful efficacy and improved bioavailability in Phase II and Phase III trials performed by other ‘Feasibility-to-Licensing’ associates.

Derek Chalmers, Ph.D., D.Sc., the CEO and President of Cara Therapeutics, expressed that they consider Oral CR845 has the prospect to bring considerable relief to people with CKD-aP. They are delighted that they were able to progress their work with Enteris and commence this Phase 1 trial with the potential to develop Oral CR845 into a Phase II clinical study in CKD-aP in the Q1 2018.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure